for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Palatin Technologies, Inc.

PTN

Latest Trade

0.84USD

Change

0.00(0.00%)

Volume

1,000

Today's Range

--

 - 

--

52 Week Range

0.59

 - 

1.78

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.84
Open
0.00
Volume
1,000
3M AVG Volume
26.93
Today's High
--
Today's Low
--
52 Week High
1.78
52 Week Low
0.59
Shares Out (MIL)
227.04
Market Cap (MIL)
190.64
Forward P/E
-15.27
Dividend (Yield %)
--

Latest Developments

More

Palatin Technologies Q4 Earnings Per Share $0.23

Palatin Technologies Inc - On June 24, Co Approved New Employment Agreements With Carl Spana, CEO And Stephen Wills, CFO

Palatin Technologies Says FDA Approves NDA For Vyleesi

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.

Industry

Biotechnology & Drugs

Contact Info

4B Cedarbrook Dr

+1.609.4952200

https://www.palatin.com/

Executive Leadership

John K. A. Prendergast

Chairman of the Board

Carl Spana

President, Chief Executive Officer, Director

Stephen T. Wills

Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary

Robert K. deVeer

Independent Director

Alan William Dunton

Independent Director

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.1K

2020(E)

0.0K
EPS (USD)

2017

-0.070

2018

0.120

2019

0.160

2020(E)

-0.055
Price To Earnings (TTM)
6.51
Price To Sales (TTM)
3.16
Price To Book (MRQ)
1.89
Price To Cash Flow (TTM)
5.32
Total Debt To Equity (MRQ)
0.33
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
55.55
Return on Equity (TTM)
49.77

Latest News

Latest News

FDA approves drug for loss of sexual desire in women

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".

FDA approves drug for loss of female sexual desire

The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said.

BRIEF-Palatin Technologies, Inc. Reports Q3 Earnings Per Share $0.00

* PALATIN TECHNOLOGIES, INC. REPORTS THIRD QUARTER FISCAL YEAR 2018 RESULTS; TELECONFERENCE AND WEBCAST TO BE HELD ON MAY 15, 2018

BRIEF-Palatin Technologies Says Entered Into An Equity Distribution Agreement

* PALATIN TECHNOLOGIES INC SAYS ENTERED INTO AN EQUITY DISTRIBUTION AGREEMENT - SEC FILING

REFILE-BRIEF-Palatin Technologies Presents Preclinical Data On Investigational Treatment For IBD

* PALATIN TECHNOLOGIES PRESENTS PRECLINICAL ORAL FORMULATION DATA ON PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST FOR INFLAMMATORY BOWEL DISEASES

BRIEF-Palatin Technologies Reports Q2 Earnings Per Share $0.01

* PALATIN TECHNOLOGIES, INC. REPORTS SECOND QUARTER FISCAL YEAR 2018 RESULTS; TELECONFERENCE AND WEBCAST TO BE HELD ON FEBRUARY 12, 2018

BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177

* PALATIN TECHNOLOGIES, INC. INITIATES SUBJECT DOSING IN FIRST-IN-HUMAN CLINICAL STUDY OF PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST

BRIEF-Palatin Technologies Announces FDA Clearance Of Investigational New Drug (Ind) Application For Pl-8177

* PALATIN TECHNOLOGIES INC ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR PL-8177 FOR ULCERATIVE COLITIS

BRIEF-Palatin Technologies signs licensing agreement with Kwangdong Pharma

* Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea

BRIEF-Palatin Technologies says Q1 earnings per share $0.05

* Palatin technologies, Inc. Reports first quarter fiscal year 2018 results; teleconference and webcast to be held on November 13, 2017

BRIEF-Palatin Technologies reports Q4 earnings per share of $0.07

* Palatin Technologies reports fourth quarter and fiscal year 2017 results; teleconference and webcast to be held on September 25, 2017

BRIEF-Palatin Technologies signs agreement with Fosun Pharma

* Palatin Technologies announces signing of licensing agreement with Fosun Pharma rights to bremelanotide in China and other selected territories

BRIEF-Palatin Technologies, Inc. reports first quarter 2017 results

* There were no revenues recorded in quarters ended september 30, 2016 and 2015

Exclusive: Female Viagra contender Palatin Technologies explores potential sale - source

Palatin Technologies Inc <PTN.A>, which is looking to take the throne from Addyi as the primary drug treatment for low sex drive in women, has hired an investment bank to explore a sale or licensing deal, according to a source familiar with the matter.

BRIEF-Bremelanotide meets co-primary endpoints in advanced trials for hypoactive sexual desire disorder

* Palatin Technologies Inc - new drug application (nda) to FDA targeted for second half of 2017 for Bremelanotide

Palatin female sexual desire drug succeeds in trials; shares soar

A drug meant to boost the libido of pre-menopausal women distressed by lack of sexual desire met the main goals of a pair of late stage clinical trials, according to initial results released on Tuesday by its developer, Palatin Technologies Inc <PTN.A>, and its shares rose...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up